Wednesday, July 8, 2026

pharma · Lymphoma · Gastrointestinal Stromal Tumors · COGT

Cogent Biosciences

Cogent Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker COGT. Primary therapeutic focus areas include Lymphoma, Gastrointestinal Stromal Tumors, Advanced Systemic Mastocy

275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US HQ
2014 Founded
283 Employees
Public company Type
COGT · NYSE Ticker
Company details
Status
Public
HQ
275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US
Founded
2014
Employees
283
Programs
13
Drugs
8
Patents
10
Clinical program

ACTR T Cell Product

Phase 1 · mab · Solid Tumor

ACTR T Cell Product for Solid Tumor is a Phase 1 program (mab) at Cogent Biosciences with 1 ClinicalTrials.gov record(s).

Internal code ATTCK-34-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cogent Biosciences
Phase
Phase 1
Modality
mab
Indication
Solid Tumor
Status
terminated
Trials
1